Survodutide
An investigational dual-agonist obesity and metabolic-disease candidate that shows up in next-wave incretin discussions.
This compound has a genuine development or study trail, but it is not an approved routine drug.
This profile is grouped by its dominant research and market lane, not by vendor shelf placement.
No major aliases are tracked for this profile yet.
No FDA label signal · 24 trials · 67 PubMed results
Survodutide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Survodutide has 18 name-matched clinical trials (highest phase: Phase 3) and 67 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What survodutide is
Survodutide is an investigational metabolic-disease candidate that appears in discussions about the next generation of obesity and liver-disease therapies.
Why it matters
If semaglutide, tirzepatide, and retatrutide define the current public conversation, compounds like survodutide help map where that pipeline may be heading next.
Regulatory context
Survodutide is not FDA approved in the United States. It belongs firmly in the investigational category.
Practical reading note
Pipeline names can move from niche to highly visible very quickly, so having a place for them in the library before approval helps keep the taxonomy current without pretending they are established drugs.